We place a high value upon training the next generation of researchers both non-clinical and clinical in a collaborative environment to deliver translational outcomes; however, we also place equal value on the patients and general public whose experience, talents and stories enrich the life of the Institute.
Since 2000, as part of Queen Mary University of London, the William Harvey Research Institute (WHRI) and the School of Medicine (SMD) have gone from strength to strength. In the 2000 Research Assessment Exercise, SMD was ranked overall 5th in the UK for world-leading or internationally excellent research. Over this same period, the School’s research spend increased from £18.7m to over £60m.
Our primary research focus and excellence lies in our cardiovascular, inflammation and endocrine research themes. In addition we are home to international excellence in critical care and renal research. We aim to combine talents from different disciplines, such as genomics, cell biology, pharmacology, with translational bench to patient studies and large-scale clinical trials, all with the ambition of therapeutic innovation.
We are currently the largest pharmacological research institute in the UK University sector and one of the largest in Europe. We have grown from 140 people, in 2002, to number, in 2019, over 530 clinicians and scientists from 45 countries.
The 100,000 Genomes Project, led by Genomics England in partnership with NHS England, is a ground-breaking programme which has been based at our Charterhouse Square Campus since 2013 and involves several WHRI researchers, including Chief Scientist and Interim Chief Executive Professor Mark Caulfield.